Kieger Healthcare Chart of the Month – Kieger
icon-menu-open Created with Sketch.
icon-menu-close Created with Sketch.
Kieger
icon-arrow Created with Sketch. icon-arrow Created with Sketch.
News
icon-arrow Created with Sketch. icon-arrow Created with Sketch.
Kieger Healthcare Chart of the Month

Kieger Healthcare Chart of the Month

It is estimated, that globally more than 300 million people suffer from depression. Latest research has shown that the pandemic might has added another 50 million on top of that. Sadly, 1 in 3 patients do not benefit from current available treatments and develop treatment resistant depression over time.

Unfortunately, there are not a lot of options left for those patients. While there have been more than 80 drugs approved in oncology since 2015 it was only 7 in mental health.

The Kieger Impact Healthcare Fund has a strong focus on mental health and also investing in new and more holistic psychedelic therapies.

The field of psychedelic drugs has been re-emerging quite a lot over the last years with very good and promising clinical data and also FDA breakthrough designations for example for a psylocibin therapy. Psylocibin is the active psychedelic substance in more than 200 fungi worldwide.

Hopefully, these new and more holistic therapies will soon help millions of people around the globe to get back to their families and friends, to get back to work and also to get back to joy in their lifes.

Link to our funds: https://kieger.com/ucits/

Advertisement: https://kieger.com/advertisement/

Related News

Healthcare
26. September 2022

Kieger Healthcare Chart of the Month

Did you know that R&D expenses of the 15 biggest pharma companies have increased by almost 50% since 2016 to USD 133 bn in 2021? And expenses will continue to increase. Roche alone for example will spend close to CHF 15 bn on R&D in 2022, 1 bn more than in 2021.

Healthcare
16. September 2022

ESMO (European Society for Medical Oncology) 2022 in Paris

We attended the ESMO (European Society for Medical Oncology) annual oncology congress in Paris from Sept. 9-13. We came away very positive from the meeting, though two souls remain in our chest. On one side we see the amazing potential and the opportunities for new oncology therapies. On the other side complexity seems to potentially increase and so does competition in the space. But what to do as an investor? Find some proposals in our ESMO Thoughts from the Street.

Healthcare
12. September 2022

Goldman Sachs European Medtech Conference

September is traditionally one of the most important conference months, as second quarter reporting is largely complete and third quarter reporting has not yet started. We attended the 19th annual Goldman Sachs European Medtech and HC Services Conference 2022, held in London on September 7-8, again in a physical setting. While we remain mindful of all the sector headwinds, we left the conference more convinced that there are selectively attractive investment opportunities at current levels.

Contact

icon-menu-close Created with Sketch.

Get in contact with us by using the form below or via telephone. We look forward to hearing from you.

Something is wrong
Something is wrong
Something is wrong
Something is wrong
Something is wrong
Something is wrong
Something is wrong
Something went wrong. Try again later.

Thank you!

Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem.

Kieger jobs

icon-menu-close Created with Sketch.

There are no job vacancies at the moment.